When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ‐ <scp>PET</scp> Centiloid 15, Mean Age of 66 Years
Plasma Aβ42/40 ratio presents a step-like function of peripheral change shortly before the detection of plaques by Aβ-PET. Results are consistent with plasma Aβ42/40 falling to a steady-state level in participants with Aβ-PET levels greater than approximately 14CL for both assays. The age at which this occurs is dependent on APOE ε4 carriership, consistent with the approximate 7-year age difference in Centiloid abnormality between carriers and non-carriers. ANN NEUROL 2026.
Authors
- C. L. Rowe
- L. Shaw
- Azadeh Feizpour
- Rikio Katou
- Timothy Cox (ORCID: https://orcid.org/0000-0002-7232-5096)
- Ovod Vitaliy
- Rosita Shishegar
- Pierrick Bourgeat
- Yan Li
- Jurgen Fripp
- Colin L. Masters
- Takeshi Ikeuchi
- Hamid R. Sohrabi
- Michael W. Weiner
- Akinori Nakamura
- Randall J. Bateman
- Tenielle Porter
- Suzanne E. Schindler
- Tammie L.S. Benzinger
- Takeshi Iwatsubo
- Rodrigo Cánovas
- Ralph N. Martins
- John C. Morris
- Christopher J. Fowler
- Stephanie Rainey‐Smith
- Simon M. Laws
- for the Alzheimer's Disease Neuroimaging Initiative
- Paul Maruff
- James D. Doecke
Institutions
- Edith Cowan University (AU)
- Prostate Cancer Foundation of Australia (AU)
- Murdoch University (AU)
- The University of Western Australia (AU)
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- Curtin University (AU)
- Florey Institute of Neuroscience and Mental Health (AU)
- German Center for Neurodegenerative Diseases (DE)
- National Center of Neurology and Psychiatry (JP)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Australian e-Health Research Centre (AU)
- Australian Alzheimer’s Research Foundation (AU)
- National Center for Geriatrics and Gerontology (JP)
- Austin Health (AU)
- Niigata University (JP)
- The University of Tokyo (JP)
- University of San Francisco (US)
- University of Pennsylvania (US)
- Macquarie University (AU)
Publication Details
- Journal
- Annals of Neurology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1002/ana.78163
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Larry L. Hillblom Foundation
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- California Department of Public Health
- Biogen
- University of Southern California
- F. Hoffmann-La Roche
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Japan Agency for Medical Research and Development
- Northern California Institute for Research and Education
- Commonwealth Scientific and Industrial Research Organisation
- Australian Catholic University
- Eisai
- Servier
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- University of California, San Francisco
- Avid Radiopharmaceuticals
- Canadian Institutes of Health Research
- National Health and Medical Research Council
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke
- Johnson and Johnson Pharmaceutical Research and Development
- Janssen Alzheimer Immunotherapy Research And Development